144.437 -

-0.553 (-0.38%)
Range 142.679 - 146.130   (2.42%)
Open 144.230
Previous Close 144.990
Bid Price 144.420
Bid Volume 14
Ask Price 144.540
Ask Volume 37
Volume 1,424,892
Value 154,861,369
Remark -
Delayed prices. Updated at 17 Mar 2026 00:10.
Data powered by
View All Events

About Gilead Sciences

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.

There are 30 followers

Followers
0
Followers
0
Followers
0
Followers
0
Followers
0
Followers
0
Followers
0
Followers
4
Followers
0
Followers
0
Corporate attorney
Followers
44
Co-founder of The Snowball Website: www.thesnowball.info Free Telegram: https://t.me/thesnowballinfo
Followers
13
Followers
0
Followers
4
Followers
0
Followers
6
Followers
0
Beginner, learner.
Followers
17
Followers
0
Followers
2
Followers
0
Followers
0
Followers
0
Followers
0
Followers
0
Trade what the chart tells you! 20% FA 80% TA. Method: Clean chart, Volume, S/R, MA 200 Simplicity is great!
Followers
15
Followers
0
Followers
0
Followers
0
Followers
0